65Plus: open-label study of bevacizumab in combination with pemetrexed or pemetrexed/carboplatin as first-line treatment of patients with advanced or recurrent nonsquamous non-small-cell lung cancer

65Plus: open-label study of bevacizumab in combination with pemetrexed or pemetrexed/carboplatin as first-line treatment of patients with advanced or recurrent nonsquamous non-small-cell lung cancer

Wolfgang Schuette,1 Claus-Peter Schneider,2,3 Walburga Engel-Riedel,4 Christian Schumann,5,6 Martin Kohlhaeufl,7 Monika Heidi Ursel Serke,8 Gert Hoeffken,9 Cornelius Kortsik,10 Martin Reck11 1Department of Internal Medicine II, Hospital Martha-Maria Halle-Doelau, Halle, 2Department of Pneum...

Full description

Bibliographic Details
Main Authors: Schuette W, Schneider CP, Engel-Riedel W, Schumann C, Kohlhaeufl M, Serke MHU, Hoeffken G, Kortsik C, Reck M
Format: Article
Language:English
Published: Dove Medical Press 2017-11-01
Series:Lung Cancer: Targets and Therapy
Subjects:
Bevacizumab
Pemetrexed
Carboplatin
NSCLC
elderly patients
Online Access:https://www.dovepress.com/65plus-open-label-study-of-bevacizumab-in-combination-with-pemetrexed--peer-reviewed-article-LCTT

Internet

https://www.dovepress.com/65plus-open-label-study-of-bevacizumab-in-combination-with-pemetrexed--peer-reviewed-article-LCTT

Similar Items